Læknablaðið - 01.02.2022, Blaðsíða 30

90 L ÆKNABL AÐIÐ 2022/108
Heimildir
1. Luo Y, Tian X, Wang X. Diagnosis and Treatment of Cerebral Venous Thrombosis: A
Review. Front Aging Neurosci 2018; 10: 2.
2. Sveinsson ÓÁ, Kjartansson Ó, Valdimarsson EM. Stokkasegi - sjaldgæfur sjúkdómur en
mikilvæg mismunagreining við höfuðverk, heilablóðfall og flog: Tilfellaröð með yfirliti.
Læknablaðið 2013; 99: 189-95.
3. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6: 162-
70.
4. Coutinho JM, Zuurbier SM, Aramideh M, et al. The Incidence of Cerebral Venous
Thrombosis: A Cross-Sectional Study. Stroke 2012; 43: 3375-7.
5. Devasagayam S, Wyatt B, Leyden J, et al. Cerebral Venous Sinus Thrombosis Incidence Is
Higher Than Previously Thought. Stroke 2016; 7: 2180-2.
6. Otite FO, Patel S, Sharma R, et al. Trends in incidence and epidemiologic characteristics of
cerebral venous thrombosis in the United States. Neurology 2020; 95: e2200-e13.
7. Saposnik G, Barinagarrementeria F, Brown RD, et al. Diagnosis and Management of
Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American
Heart Association/American Stroke Association. Stroke 2011; 42: 1158-92.
8. Stam J. Thrombosis of the Cerebral Veins and Sinuses. N Engl J Med 2005; 352: 1791-8.
9. Alet M, Ciardi C, Aleman A, et al. Cerebral venous thrombosis in Argentina: clinical pres-
entation, predisposing factors, outcomes and literature review. J Stroke Cerebrovasc Dis
2020; 29: 105145.
10. Duman T, Uluduz D, Midi I, et al. A Multicenter Study of 1144 Patients with Cerebral
Venous Thrombosis: The VENOST Study. J Stroke Cerebrovasc Dis 2017; 26: 1848-57.
11. Ferro JM, Canhao P, Stam J, et al. Prognosis of Cerebral Vein and Dural Sinus Thrombosis:
Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).
Stroke 2004; 35: 664-70.
12. Ruiz-Sandoval JL, Chiquete E, Banuelos-Becerra LJ, et al. Cerebral Venous Thrombosis in
a Mexican Multicenter Registry of Acute Cerebrovascular Disease: The RENAMEVASC
Study. J Stroke Cerebrovasc Dis 2012; 21: 395-400.
13. Sassi SB, Touati N, Baccouche H, et al. Cerebral Venous Thrombosis: A Tunisian Monocenter
Study on 160 Patients. Clin Appl Thromb Hemost 2016; 23: 1005-9.
14. Kristoffersen ES, Harper CE, Vetvik KG, et al. Incidence and Mortality of Cerebral Venous
Thrombosis in a Norwegian Population. Stroke 2020; 51: 3023-9.
15. Ferro JM, Canhao P, Aguiar De Sousa D. Cerebral venous thrombosis. La Presse Médicale
2016; 45: e429-e50.
16. Amoozegar F, Ronksley PE, Sauve R, et al. Hormonal Contraceptives and Cerebral Venous
Thrombosis Risk: A Systematic Review and Meta-Analysis. Front Neurol 2015; 6: 7.
17. Bajko Z, Motataianu A, Stoian A, et al. Gender Differences in Risk Factor Profile and Clinical
Characteristics in 89 Consecutive Cases of Cerebral Venous Thrombosis. J Clin Med 2021;
10: 1382.
18. de Bruijn SFTM, Stam J, Koopman MMW, et al. Case-control study of risk of cerebral
sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic
conditions. BMJ 1998; 316: 589-92.
19. Silvis SM, Lindgren E, Hiltunen S, et al. Postpartum Period Is a Risk Factor for Cerebral
Venous Thrombosis: A Case-Control Study. Stroke 2019; 50: 501-3.
20. Silvis SM, Middeldorp S, Zuurbier SM, et al. Risk Factors for Cerebral Venous Thrombosis.
Semin Thromb Hemost 2016; 42: 622-31.
21. Boehme AK, Esenwa C, Elkind MSV. Stroke Risk Factors, Genetics, and Prevention. Circ Res
2017; 120: 472-95.
22. Narayan D, Kaul S, Ravishankar K, et al. Risk factors, clinical profile, and long-term
outcome of 428 patients of cerebral sinus venous thrombosis: Insights from Nizam’s
Institute Venous Stroke Registry, Hyderabad (India). Neurol India 2012; 60: 154-9.
23. Wasay M. Cerebral Venous Thrombosis: Analysis of a Multicenter Cohort From the United
States. J Stroke Cerebrovasc Dis 2008; 17: 49-54.
24. Ferro JM, Coutinho JM, Dentali F, et al. Safety and Efficacy of Dabigatran Etexilate vs Dose-
Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical
Trial. JAMA Neurol 2019; 76: 1457-65.
25. Li H, Yao M, Liao S, et al. Comparison of Novel Oral Anticoagulants and Vitamin K
Antagonists in Patients With Cerebral Venous Sinus Thrombosis on Efficacy and Safety: A
Systematic Review. Front Neurol 2020; 11: 597623.
26. Ferro JM, Bousser MG, Canhao P, et al. European Stroke Organization guideline for the
diagnosis and treatment of cerebral venous thrombosis - Endorsed by the European
Academy of Neurology. Eur J Neurol 2017; 24: 1203-13.
27. Canhao P, Ferro JM, Lindgren AG, et al. Causes and Predictors of Death in Cerebral Venous
Thrombosis. Stroke 2005; 36: 1720-25.
28. Ghosh R, Roy D, Mandal A, et al. Cerebral venous thrombosis in COVID-19. Diabetes Metab
Syndr 2021; 15: 1039-45.
E N G L I S H S U M M A R Y
Dagný Ásgeirsdóttir1
Ingvar H. Ólafsson2
Ólafur Árni Sveinsson1,3
1University Iceland, Faculty of Medicine, 2Department of
Neurosurgery, University Hospital of Iceland, Reykjavik, Iceland,
3Department of Neurology, University Hospital of Iceland,
Reykjavik, Iceland.
Correspondence: Olafur Sveinsson, olafursv@landspitali.is
Key words: cerebral sinus thrombosis, incidence, cerebral infarction,
intracranial hemorrhage, anitcoagulation
The incidence of sinus thrombosis in Iceland 2008-2020
BACKGROUND: Cerebral venous sinus thrombosis (CSVT) is the cause of 0.5%-1% of all strokes.
CSVT can cause haemorrhage, cerebral infarction and increased intracranial pressure. Due
to a variety of symptoms, CSVT can be difficult to diagnose. The purpose of this study was to
examine the incidence of CSVT in Iceland 2008-2020, risk factors, symptoms, treatment and
outcome.
METHODS: A retrospective reviewing of medical records of those diagnosed with CSVT from 1.
January 2008 to 31. December 2020, was performed. Sex, age at diagnosis, symptoms, known
risk factors, imaging results, treatment and outcome were studied. Statistical processing was
performed with Excel and Rstudio.
RESULTS: Overall, 31 patients were diagnosed with CSVT (22 women). The mean incidence was
0.72/100.00 per year. The mean age was 34.3 years (14-63 years). The most common symptom
was headache (87%), other symptoms included focal symptoms and seizures. The most
common risk factor was the use of oral contraceptives (73%). Four patients had no risk factor.
The most commonly affected sinus was the transverse-sinus (74%). All patients were treated
with anticoagulants. Most received heparin or low-molecular-weight heparin then succeeded
by warfarin or NOACs. Three months after diagnosis, 87% of the patients scored 0-2 on the
modified Rankin Scale. One patient died as a result of CSVT.
DISCUSSION: The incidence of CSVT in Iceland is in accordance with other studies. Headache
was the most common symptom and oral contraceptives the most common risk factor
among women. Most patients made a good recovery, which suggests a timely diagnosis and
appropriate treatment for CSVT in Iceland.
doi 10.17992/lbl.2022.02.677
R A N N S Ó K N